BridgeMD
New treatment option for Dexmedetomidine
Official title Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery
ClinicalTrials.gov ID: NCT06614010
What this study is testing
What is Dexmedetomidine Injection?
Dexmedetomidine Injection is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for dexmedetomidine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To examine the impact of various administration routes of dexmedetomidine in conjunction with ultrasound-guided fascia iliaca block (FIB) on emergence agitation (EA) during the postoperative recovery period after hip replacement surgery.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- age between 18 and 65 years, with no restriction on gender
- diagnosis of hip joint disease necessitating hip arthroplasty
- ASA grade I-II
- no significant cardiopulmonary, hepatic, or renal dysfunction prior to the operation
- no history of psychiatric disorders or long-term use of sedative medications prior to the operation
You likely can't join if
- patients allergic to or with contraindications to ropivacaine or dexmedetomidine
- patients exhibiting symptoms of agitation or delirium prior to the procedure
- patients with severe central or peripheral nervous system disorders
- patients with coagulation disorders or receiving anticoagulant therapy
- pregnant or breastfeeding women
- patients who received other medications or treatments prior to the procedure that might affect the study results
See the full eligibility criteria
- age between 18 and 65 years, with no restriction on gender
- diagnosis of hip joint disease necessitating hip arthroplasty
- ASA grade I-II
- no significant cardiopulmonary, hepatic, or renal dysfunction prior to the operation
- no history of psychiatric disorders or long-term use of sedative medications prior to the operation
- signing of an informed consent form to voluntarily participate in the study.
- patients allergic to or with contraindications to ropivacaine or dexmedetomidine
- patients exhibiting symptoms of agitation or delirium prior to the procedure
- patients with severe central or peripheral nervous system disorders
- patients with coagulation disorders or receiving anticoagulant therapy
- pregnant or breastfeeding women
- patients who received other medications or treatments prior to the procedure that might affect the study results
- patients unable to cooperate with the study or intolerant to ultrasound-guided iliofascial block
The study team makes the final eligibility decision.
Where it's taking place
- Jinan, Shandong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jinan, Shandong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.